TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $162,753 | -42.4% | 18,205 | -1.0% | 0.00% | – |
| Q2 2023 | $282,347 | -21.2% | 18,382 | +15.4% | 0.00% | – |
| Q1 2023 | $358,266 | +1.2% | 15,930 | -5.4% | 0.00% | – |
| Q4 2022 | $353,998 | -56.1% | 16,833 | -48.6% | 0.00% | -100.0% |
| Q3 2022 | $807,000 | -46.3% | 32,747 | -47.2% | 0.00% | 0.0% |
| Q2 2022 | $1,504,000 | +565.5% | 62,045 | +753.8% | 0.00% | – |
| Q4 2021 | $226,000 | -18.4% | 7,267 | -36.5% | 0.00% | – |
| Q3 2021 | $277,000 | +42.8% | 11,442 | -14.0% | 0.00% | – |
| Q2 2021 | $194,000 | -66.4% | 13,298 | -42.5% | 0.00% | – |
| Q1 2021 | $577,000 | -7.7% | 23,113 | +0.9% | 0.00% | – |
| Q4 2020 | $625,000 | – | 22,903 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |